top of page
Press Releases
December 15, 2025
March 20, 2025
April 26, 2023
May 13, 2021
June 12, 2019
The Lundquist Institute and Its Start-Up Company Vitalex Biosciences Announce Strategic Advancement of Second-Generation Fungal Vaccine VXV-01 Through Phase 1 Trials Under $40 Million Competitive Contract From NIH/NIAID
Antibody-based therapy is several steps closer to treat lethal mucormycosis
Lundquist Institute Start-Up Vitalex Biosciences Awarded Grant from NIAID/NIH
Lundquist Institute Investigator Ashraf Ibrahim, PhD, Leads Life-Saving Research on Mucormycosis, the Deadly “Black Fungus”
LA BioMed Scientists Make Breakthrough on Potential Vaccine For Deadly Fungal Infection
bottom of page